Recursion Pharmaceuticals Stock (NASDAQ:RXRX)
Previous Close
$6.27
52W Range
$5.70 - $15.74
50D Avg
$6.66
200D Avg
$8.38
Market Cap
$1.69B
Avg Vol (3M)
$5.13M
Beta
0.80
Div Yield
-
RXRX Company Profile
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Performance
Peer Comparison
Ticker | Company |
---|---|
SANA | Sana Biotechnology, Inc. |
XFOR | X4 Pharmaceuticals, Inc. |
CNSP | CNS Pharmaceuticals, Inc. |
CWBR | CohBar, Inc. |
VECT | VectivBio Holding AG |
DAWN | Day One Biopharmaceuticals, Inc. |
RLAY | Relay Therapeutics, Inc. |
ABSI | Absci Corporation |
AVRO | AVROBIO, Inc. |
INZY | Inozyme Pharma, Inc. |
EFTR | eFFECTOR Therapeutics, Inc. |
AFMD | Affimed N.V. |
IMMX | Immix Biopharma, Inc. |
ABOS | Acumen Pharmaceuticals, Inc. |
OCEA | Ocean Biomedical, Inc. |
HEPA | Hepion Pharmaceuticals, Inc. |
ENVB | Enveric Biosciences, Inc. |